Hemolytic-Uremic Syndrome Medication

Updated: Dec 13, 2018
  • Author: Malvinder S Parmar, MBBS, MS, FRCPC, FACP, FASN; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP  more...
  • Print

Medication Summary

Eculizumab (Soliris) is approved by the U.S. Food and Drug Administration for the treatment of hemolytic-uremic syndrome (HUS) that is not associated with Shiva-like toxin (non–Stx-HUS; atypical HUS). Supportive care only is used for Stx-HUS (typical HUS). Medications for supportive care may include angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs)for control of hypertension, or phenytoin for prevention of seizures.


Monoclonal Antibodies

Class Summary

Agents in this category may block the formation of membrane attack complex, which can stabilize the hemoglobin and reduce the need for RBC transfusions.

Eculizumab (Soliris)

Monoclonal blocking antibody to complement protein C5; inhibits cleavage to C5a and C5b, thus preventing terminal complement complex C5b-9, thereby preventing RBC hemolysis

Inhibits terminal complement mediated intravascular hemolysis in PNH patients and complement-mediated thrombotic microangiopathy (TMA) in patients with aHUS